A recent study indicates that people who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who end traditional lifestyle regimens.
Findings released in a prominent health publication shows that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments should be aware of the danger of fast weight regain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The analysis, which examined 37 of studies involving thousands of participants, compared the outcomes of these new drugs with other pills.
Researchers note that individuals who shed pounds through lifestyle changes alone usually experience a slower weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Experts propose the mechanism of the injections accounts for the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal could lead to the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in hunger is unsuppressed, making overeating much more probable."
A Chronic Condition?
Health authorities advise the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the therapy is often ongoing.
This perspective is supported by pharmaceutical companies, who state that the findings "emphasize the long-term character of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have come off the medication report a intense resurgence of appetite.
"I experienced something flipping and you become ravenous," recalled a patient.
The struggle is exacerbated if patients have not established lasting lifestyle or habit changes during treatment.
Significant Use
Survey data suggest that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while these medications are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated behavioural management.
